A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer

The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy B cells that enhance the target cell lysis and cytokine secretion through repetitive stimulation. Here, we report to ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Hombach, Andreas A., Ambrose, Christine, Lobb, Roy, Rennert, Paul, Abken, Hinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856536/
https://www.ncbi.nlm.nih.gov/pubmed/36672182
http://dx.doi.org/10.3390/cells12020248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856536/
https://www.ncbi.nlm.nih.gov/pubmed/36672182
http://dx.doi.org/10.3390/cells12020248

Ejemplares similares